Opdivo® (nivolumab) – Updated indication
March 7, 2019 - The FDA approved Bristol-Myers Squibb’s Opdivo (nivolumab), for the treatment of patients with unresectable or metastatic melanoma, as a single agent or in combination with Yervoy® (ipilimumab).
Download PDF
